CM
XENT

Castleark Management’s Intersect ENT, Inc XENT Stock Holding History

Castleark Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-134,944
Closed -$5.3M – 441
2018
Q1 		$5.3M Sell
134,944
-31,401
-19% -$1.15M 0.17% 177
2017
Q4 		$5.39M Sell
166,345
-117,420
-41% -$3.52M 0.16% 180
2017
Q3 		$8.84M Buy
+283,765
New +$8.4M 0.28% 131
2015
Q4 		– Sell
-230,412
Closed -$5.39M – 426
2015
Q3 		$5.39M Buy
230,412
+13,823
+6% +$381K 0.17% 149
2015
Q2 		$6.2M Buy
+216,589
New +$5.68M 0.17% 163

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Castleark Management's XENT Position: Q2 2018 in Review

Castleark Management sold out of Intersect ENT, Inc (XENT) in Q2 2018, closing a stake of 134,944 shares — an estimated $5.3M sold.

Castleark Management first reported a position in XENT in Q2 2015 and held it in 5 quarters. The position peaked at $8.84M in Q3 2017. 160 funds tracked by Wall St. Rank hold XENT as of Q2 2018.

  • Castleark Management reported no remaining Intersect ENT, Inc position as of Q2 2018 after selling out during the quarter.
  • Castleark Management sold 134,944 Intersect ENT, Inc shares in Q2 2018, an estimated $5.3M.
  • Castleark Management first reported a position in Intersect ENT, Inc in Q2 2015 and held it in 5 quarters.
  • Castleark Management's Intersect ENT, Inc position peaked at $8.84M in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2018.

Based on Castleark Management's 13F filing for Q2 2018, filed 15 Aug 2018.